Please be aware that all information shared here at Canada Pharmacy has been medically reviewed and fact-checked for accuracy. These verifications are made by board-certified medical professionals who have the authority required to state that information related to medical conditions, symptoms, procedures and tests, and standard treatment protocols is valid and truthful. This is based on current guidelines and consensuses shared amongst medical professionals, and in representation of the latest research.
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Also Known as Ryeqo
Sign up to get exclusive coupon discounts and be the first to be notified when we have this product available.
Ryeqo is indicated for treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. One tablet of Ryeqo must be taken once daily, at about the same time with or without food. Tablets should be taken with some liquid as needed. Ryeqo can be taken without interruption. Discontinuation should be considered when the patient enters menopause, as uterine fibroids are known to regress when menopause begins.
Lactose monohydrate Mannitol (E421) Sodium starch glycolate Hydroxypropyl cellulose (E463) Magnesium stearate (E572) Hypromellose type 2910 (E464) Titanium dioxide (E171) Triacetin (E1518) Iron oxide yellow (E172)
In patients with risk factors for osteoporosis or bone loss, a dual X-ray absorptiometry (DXA) is recommended prior to starting Ryeqo treatment.
Psychiatric disorders - Irritability Vascular disorders - Hot flush Gastrointestinal disorders - Dyspepsia Skin and subcutaneous tissue disorders - Alopecia , Hyperhidrosis , Night sweats Reproductive system and breast disorders - Uterine bleeding , Breast cyst, Libido decreased